Acadia Pharmaceuticals Stock
Price
Target price
€23.57
€23.57
3.110%
0.71
3.110%
€27.38
05.12.25 / Tradegate
WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals dominated the market today, gaining €0.71 (3.110%).
With 27 Buy predictions and 1 Sell predictions Acadia Pharmaceuticals is one of the favorites of our community.
As a result the target price of 27 € shows a slightly positive potential of 14.55% compared to the current price of 23.57 € for Acadia Pharmaceuticals.
For the coming years our community has positive and negative things to say abot the Acadia Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 3.110% | 10.089% | 21.276% | 44.247% | 46.625% | 57.680% | -47.265% |
| Ironwood Pharmaceuticals | 0.640% | -5.422% | 96.250% | -1.258% | -25.238% | -72.653% | -67.959% |
| Novocure Ltd | 2.370% | -6.222% | 2.868% | -58.648% | -64.286% | -86.012% | -91.451% |
| Iovance Biotherapeutics Inc. | 0.210% | -11.285% | 19.316% | -76.411% | -72.702% | -75.402% | -94.690% |
Comments
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $31.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target lowered by analysts at Royal Bank Of Canada from $34.00 to $32.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat